Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/Line 38	Abstract/ Paragraph 2
		( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2/Line 38-59	Abstract/ Paragraph 2-3
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 3-4/Line 70- 112	Introduction/ Paragraph 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4-5/Line 113-120	Introduction/ Paragraph 4
Methods				
Study design	4	Present key elements of study design early in the paper	Page 5/Line 124- 128	Methods/ Paragraph 2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5/Line 124- 135	Methods/ Paragraph 2
Participants	6	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page 5/Line 126- 132	Methods/ Paragraph 2
		( <i>b</i> ) For matched studies, give matching criteria and number of exposed and unexposed	Page 5/Line 126- 128	Methods/ Paragraph 2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5-6/Line 134-151	Methods/ Paragraph 1-2
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6-7/Line 152-201	Methods/ Paragraph 2-6
Bias	9	Describe any efforts to address potential sources of bias	Page 7/Line 196- 201	Methods/ Paragraph 6
Study size	10	Explain how the study size was arrived at	Page 5/ Line 124- 128	Methods/ Paragraph 1

Quantitative	11	Explain how quantitative variables	Page 7-8/Line	Methods/
variables		were handled in the analyses. If	202-213	Paragraph 7
		applicable, describe which		
		groupings were chosen and why		
Statistical methods	12	( <i>a</i> ) Describe all statistical methods,	Page 7-8/Line	Methods/
		including those used to control for	202-213	Paragraph 7
		confounding		
		(b) Describe any methods used to	Page 7-8/Line	Methods/
		examine subgroups and interactions	202-213	Paragraph 7
		(c) Explain how missing data were	Page 7-8/Line	Methods/
		addressed	202-213	Paragraph 7
		(d) If applicable, explain how loss	NA	No missing data
		to follow-up was addressed	1 1 1 1	Tto missing data
		( <u>e</u> ) Describe any sensitivity	Page 7-8/Line	Methods/
			202-213	
		analyses	202-213	Paragraph 7
Results		1		
Participants	13*	(a) Report numbers of individuals at	Page 8/Line 217-	Results/ Paragraph
		each stage of study—eg numbers	222	1
		potentially eligible, examined for		
		eligibility, confirmed eligible,		
		included in the study, completing		
		follow-up, and analysed		
		(b) Give reasons for non-	NA	All patients are
		participation at each stage		enrolled
		(c) Consider use of a flow diagram	NA	The process of
				selection is simple
				to know
Descriptive data	14*	(a) Give characteristics of study	Page 8/Line 223-	Results/ Paragraph
-		participants (eg demographic,	231	2
		clinical, social) and information on		
		exposures and potential		
		confounders		
		(b) Indicate number of participants	NA	No missing data
		with missing data for each variable	1 11 1	i to missing uuu
		of interest		
		(c) Summarise follow-up time (eg,	NA	No follow-up
		average and total amount)	1112	rvo ronow-up
Outcome data	15*	Report numbers of outcome events	Page 8-9/Line	Results/ Paragraph
Outcome data	15	or summary measures over time	233-262	3-5
Main regulta	16	•		
Main results	16	( <i>a</i> ) Give unadjusted estimates and,	Page 8-9/Line	Results/ Paragraph
		if applicable, confounder-adjusted	233-262	3-5
		estimates and their precision (eg,		
		95% confidence interval). Make		
		clear which confounders were		
		adjusted for and why they were		
		included		
		(b) Report category boundaries	Page 5-6/Line	Methods/
		when continuous variables were	144-151	Paragraph 2
	1	categorized	1	

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA	No other analyses done
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 10/Line 274- 280	Discussion/ Paragraph 2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 12/Line 343- 350	Discussion/ Paragraph 6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 10-11/Line 280-321	Discussion/ Paragraph 2-4
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11/Line 322- 342	Discussion/ Paragraph 5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 13/Line 361- 363	Acknowledge/ Paragraph 1

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/apm-20-1125

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.